A phase II trial of melphalan or thioguanine in the treatment of patients with advanced renal cell cancer

Robert S. Witte, Paul Elson, James A. Stewart, James A. Malliard, Martin M. Oken, Patrick Loehrer

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Sixty-one ambulatory patients with advanced or unresectable renal carcinoma were treated with either melphalan (41 patients) or thioguanine (20 patients). Two objective partial responses were observed in the melphalan cohorts for a response rate of 4.9% (exact 95% confidence interval, 1-17%). No patients treated with thioguanine responded. One patient died of hemorrhage on the melphalan arm. There were no treatment-related deaths on the thioguanine arm. Other than the one death, there were no unexpected or irreversible toxicities. Myelosuppression was the most frequent toxicity. These agents have no meaningful activity in the treatment of advanced renal cell carcinoma.

Original languageEnglish
Pages (from-to)96-98
Number of pages3
JournalUrologic Oncology: Seminars and Original Investigations
Volume2
Issue number3
DOIs
StatePublished - May 1996

Fingerprint

Thioguanine
Melphalan
Renal Cell Carcinoma
Therapeutics
Confidence Intervals
Hemorrhage
Carcinoma
Kidney

Keywords

  • chemotherapy
  • melphalan
  • Renal cell cancer
  • thioguanine

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

A phase II trial of melphalan or thioguanine in the treatment of patients with advanced renal cell cancer. / Witte, Robert S.; Elson, Paul; Stewart, James A.; Malliard, James A.; Oken, Martin M.; Loehrer, Patrick.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 2, No. 3, 05.1996, p. 96-98.

Research output: Contribution to journalArticle

Witte, Robert S. ; Elson, Paul ; Stewart, James A. ; Malliard, James A. ; Oken, Martin M. ; Loehrer, Patrick. / A phase II trial of melphalan or thioguanine in the treatment of patients with advanced renal cell cancer. In: Urologic Oncology: Seminars and Original Investigations. 1996 ; Vol. 2, No. 3. pp. 96-98.
@article{e31e84d672ad47b6b1aaeab8b028181e,
title = "A phase II trial of melphalan or thioguanine in the treatment of patients with advanced renal cell cancer",
abstract = "Sixty-one ambulatory patients with advanced or unresectable renal carcinoma were treated with either melphalan (41 patients) or thioguanine (20 patients). Two objective partial responses were observed in the melphalan cohorts for a response rate of 4.9{\%} (exact 95{\%} confidence interval, 1-17{\%}). No patients treated with thioguanine responded. One patient died of hemorrhage on the melphalan arm. There were no treatment-related deaths on the thioguanine arm. Other than the one death, there were no unexpected or irreversible toxicities. Myelosuppression was the most frequent toxicity. These agents have no meaningful activity in the treatment of advanced renal cell carcinoma.",
keywords = "chemotherapy, melphalan, Renal cell cancer, thioguanine",
author = "Witte, {Robert S.} and Paul Elson and Stewart, {James A.} and Malliard, {James A.} and Oken, {Martin M.} and Patrick Loehrer",
year = "1996",
month = "5",
doi = "10.1016/S1078-1439(96)00073-7",
language = "English",
volume = "2",
pages = "96--98",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - A phase II trial of melphalan or thioguanine in the treatment of patients with advanced renal cell cancer

AU - Witte, Robert S.

AU - Elson, Paul

AU - Stewart, James A.

AU - Malliard, James A.

AU - Oken, Martin M.

AU - Loehrer, Patrick

PY - 1996/5

Y1 - 1996/5

N2 - Sixty-one ambulatory patients with advanced or unresectable renal carcinoma were treated with either melphalan (41 patients) or thioguanine (20 patients). Two objective partial responses were observed in the melphalan cohorts for a response rate of 4.9% (exact 95% confidence interval, 1-17%). No patients treated with thioguanine responded. One patient died of hemorrhage on the melphalan arm. There were no treatment-related deaths on the thioguanine arm. Other than the one death, there were no unexpected or irreversible toxicities. Myelosuppression was the most frequent toxicity. These agents have no meaningful activity in the treatment of advanced renal cell carcinoma.

AB - Sixty-one ambulatory patients with advanced or unresectable renal carcinoma were treated with either melphalan (41 patients) or thioguanine (20 patients). Two objective partial responses were observed in the melphalan cohorts for a response rate of 4.9% (exact 95% confidence interval, 1-17%). No patients treated with thioguanine responded. One patient died of hemorrhage on the melphalan arm. There were no treatment-related deaths on the thioguanine arm. Other than the one death, there were no unexpected or irreversible toxicities. Myelosuppression was the most frequent toxicity. These agents have no meaningful activity in the treatment of advanced renal cell carcinoma.

KW - chemotherapy

KW - melphalan

KW - Renal cell cancer

KW - thioguanine

UR - http://www.scopus.com/inward/record.url?scp=0030135479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030135479&partnerID=8YFLogxK

U2 - 10.1016/S1078-1439(96)00073-7

DO - 10.1016/S1078-1439(96)00073-7

M3 - Article

C2 - 21224145

AN - SCOPUS:0030135479

VL - 2

SP - 96

EP - 98

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 3

ER -